Minister for Enterprise, Trade and Employment, Simon Coveney TD, Minister for Further and Higher Education, Research, Innovation and Science, Simon Harris TD and the Minister of State for Trade Promotion, Digital and Company Regulation, Dara Calleary TD, recently announced funding of a further €58.8 million to 12 new projects under the Disruptive Technology and Innovation Fund (DTIF) for diverse and potentially life-changing disruptive technology projects.
Congratulations to SSPC investigators from the University of Limerick, Professor Sarah Hudson, Dr Emmet O’Reilly, Professor Vivek Ranade and Dr Kieran McGourty, who are involved in two projects funded by the Disruptive Technology and Innovation Fund (DTIF).
The projects and teams:
The Selio System is a pre-biopsy intervention device which prevents haemorrhage occurring before kidney or liver biopsy takes place, thereby facilitating same day release of patients – €4,152,688.
- Selio Medical Ltd
- InverMed Teoranta
- University of Limerick (UL) – Professor Sarah Hudson, Dr Emmett O’Reilly and Dr Kieran McGourty
- Trinity College Dublin (TCD)
The BioBridge project will make biopharmaceutical manufacturing vastly more efficient by building new laboratory methods and computer models to design better manufacturing processes – €3,182,042.
- ValitaCell Ltd
- Data Chemist Ltd T/A Terminus DB
- University of Limerick (UL) – Professor Vivek Ranade
- Digital Manufacturing Ireland (DMI) CLG
The Disruptive Technologies Innovation Fund (DTIF) is a €500 million fund established under the National Development Plan (NDP) in 2018. The Department of Enterprise, Trade and Employment manages the DTIF with administrative support from Enterprise Ireland. The purpose of the fund is to drive collaboration between Ireland’s world-class research base and industry as well as facilitating enterprises to compete directly for funding in support of the development and adoption of these technologies. The aim is to support investment in the development and deployment of disruptive technologies and applications on a commercial basis.